S&P 500   5,093.48 (+0.47%)
DOW   39,010.20 (+0.16%)
QQQ   438.95 (+0.85%)
AAPL   182.21 (+0.44%)
MSFT   407.91 (+0.05%)
META   488.27 (+0.88%)
GOOGL   137.54 (+0.85%)
AMZN   173.72 (+0.32%)
TSLA   203.94 (+0.94%)
NVDA   796.43 (+2.55%)
NIO   5.64 (+3.87%)
AMD   181.70 (+2.92%)
BABA   74.58 (-0.01%)
T   17.07 (+0.65%)
F   12.43 (+1.06%)
MU   90.15 (+0.49%)
CGC   3.40 (+1.19%)
GE   155.49 (-0.08%)
DIS   112.45 (+1.49%)
AMC   4.56 (-8.62%)
PFE   27.05 (+0.04%)
PYPL   60.95 (+1.16%)
XOM   104.80 (+0.46%)
S&P 500   5,093.48 (+0.47%)
DOW   39,010.20 (+0.16%)
QQQ   438.95 (+0.85%)
AAPL   182.21 (+0.44%)
MSFT   407.91 (+0.05%)
META   488.27 (+0.88%)
GOOGL   137.54 (+0.85%)
AMZN   173.72 (+0.32%)
TSLA   203.94 (+0.94%)
NVDA   796.43 (+2.55%)
NIO   5.64 (+3.87%)
AMD   181.70 (+2.92%)
BABA   74.58 (-0.01%)
T   17.07 (+0.65%)
F   12.43 (+1.06%)
MU   90.15 (+0.49%)
CGC   3.40 (+1.19%)
GE   155.49 (-0.08%)
DIS   112.45 (+1.49%)
AMC   4.56 (-8.62%)
PFE   27.05 (+0.04%)
PYPL   60.95 (+1.16%)
XOM   104.80 (+0.46%)
S&P 500   5,093.48 (+0.47%)
DOW   39,010.20 (+0.16%)
QQQ   438.95 (+0.85%)
AAPL   182.21 (+0.44%)
MSFT   407.91 (+0.05%)
META   488.27 (+0.88%)
GOOGL   137.54 (+0.85%)
AMZN   173.72 (+0.32%)
TSLA   203.94 (+0.94%)
NVDA   796.43 (+2.55%)
NIO   5.64 (+3.87%)
AMD   181.70 (+2.92%)
BABA   74.58 (-0.01%)
T   17.07 (+0.65%)
F   12.43 (+1.06%)
MU   90.15 (+0.49%)
CGC   3.40 (+1.19%)
GE   155.49 (-0.08%)
DIS   112.45 (+1.49%)
AMC   4.56 (-8.62%)
PFE   27.05 (+0.04%)
PYPL   60.95 (+1.16%)
XOM   104.80 (+0.46%)
S&P 500   5,093.48 (+0.47%)
DOW   39,010.20 (+0.16%)
QQQ   438.95 (+0.85%)
AAPL   182.21 (+0.44%)
MSFT   407.91 (+0.05%)
META   488.27 (+0.88%)
GOOGL   137.54 (+0.85%)
AMZN   173.72 (+0.32%)
TSLA   203.94 (+0.94%)
NVDA   796.43 (+2.55%)
NIO   5.64 (+3.87%)
AMD   181.70 (+2.92%)
BABA   74.58 (-0.01%)
T   17.07 (+0.65%)
F   12.43 (+1.06%)
MU   90.15 (+0.49%)
CGC   3.40 (+1.19%)
GE   155.49 (-0.08%)
DIS   112.45 (+1.49%)
AMC   4.56 (-8.62%)
PFE   27.05 (+0.04%)
PYPL   60.95 (+1.16%)
XOM   104.80 (+0.46%)
NASDAQ:PRPH

ProPhase Labs (PRPH) Stock Price, News & Analysis

$4.74
-0.29 (-5.77%)
(As of 02/28/2024 ET)
Today's Range
$4.72
$5.22
50-Day Range
$4.50
$5.26
52-Week Range
$4.05
$9.94
Volume
66,185 shs
Average Volume
16,703 shs
Market Capitalization
$85.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

ProPhase Labs MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.1% Upside
$11.00 Price Target
Short Interest
Bearish
2.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of ProPhase Labs in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.14 out of 5 stars

Medical Sector

621st out of 958 stocks

Pharmaceutical Preparations Industry

300th out of 450 stocks


PRPH stock logo

About ProPhase Labs Stock (NASDAQ:PRPH)

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

PRPH Stock Price History

PRPH Stock News Headlines

ProPhase Labs' (PRPH) "Buy" Rating Reaffirmed at HC Wainwright
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
PRPH Mar 2024 5.000 put
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
ProPhase Dips on Moving Karkus up Ladder
ProPhase Labs Inc (PRPH)
ProPhase hires Jed Latkin as COO
ProPhase Labs reports Q3 results
See More Headlines
Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/29/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRPH
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+132.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$18.46 million
Pretax Margin
-26.03%

Debt

Sales & Book Value

Annual Sales
$122.65 million
Cash Flow
$1.35 per share
Book Value
$3.91 per share

Miscellaneous

Free Float
13,335,000
Market Cap
$85.56 million
Optionable
Optionable
Beta
-0.32
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Ted William Karkus (Age 65)
    Chairman & CEO
    Comp: $902.2k
  • Mr. Jed A. Latkin (Age 50)
    Chief Operating Officer & Head of Finance Department
  • Mr. Robert A. Morse Jr. (Age 49)
    Controller, Principal Financial Officer & Principal Accounting Officer
  • Mr. Sergio Miralles
    Executive VP & Chief Information Officer
  • Mr. Jason Karkus
    President of Nebula Genomics
  • Mr. Kamal Obbad
    Senior VP and Director of Sales & Marketing - Nebula Genomics














PRPH Stock Analysis - Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PRPH shares.
View PRPH analyst ratings
or view top-rated stocks.

What is ProPhase Labs' stock price target for 2024?

1 analysts have issued 1-year target prices for ProPhase Labs' stock. Their PRPH share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 132.1% from the stock's current price.
View analysts price targets for PRPH
or view top-rated stocks among Wall Street analysts.

How have PRPH shares performed in 2024?

ProPhase Labs' stock was trading at $4.52 at the beginning of 2024. Since then, PRPH shares have increased by 4.9% and is now trading at $4.74.
View the best growth stocks for 2024 here
.

When is ProPhase Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PRPH earnings forecast
.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of $0.07 by $0.33. The company had revenue of $9.47 million for the quarter, compared to analysts' expectations of $9.08 million. ProPhase Labs had a negative net margin of 16.70% and a negative trailing twelve-month return on equity of 17.51%. During the same quarter in the previous year, the firm posted ($0.05) earnings per share.

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?
Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.38%), Perritt Capital Management Inc. (0.48%), Northern Trust Corp (0.25%), Goldman Sachs Group Inc. (0.21%), Bridgeway Capital Management LLC (0.13%) and Tower Research Capital LLC TRC (0.08%).
View institutional ownership trends
.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRPH) was last updated on 2/29/2024 by MarketBeat.com Staff